LRMR
Price
$4.87
Change
+$0.59 (+13.79%)
Updated
Oct 3 closing price
Capitalization
416.83M
43 days until earnings call
MDNAF
Price
$0.71
Change
-$0.01 (-1.39%)
Updated
Oct 3 closing price
Capitalization
59.23M
39 days until earnings call
Interact to see
Advertisement

LRMR vs MDNAF

Header iconLRMR vs MDNAF Comparison
Open Charts LRMR vs MDNAFBanner chart's image
Larimar Therapeutics
Price$4.87
Change+$0.59 (+13.79%)
Volume$5.73M
Capitalization416.83M
Medicenna Therapeutics
Price$0.71
Change-$0.01 (-1.39%)
Volume$111.92K
Capitalization59.23M
LRMR vs MDNAF Comparison Chart in %
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LRMR vs. MDNAF commentary
Oct 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LRMR is a StrongBuy and MDNAF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 06, 2025
Stock price -- (LRMR: $4.87 vs. MDNAF: $0.71)
Brand notoriety: LRMR and MDNAF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LRMR: 201% vs. MDNAF: 229%
Market capitalization -- LRMR: $416.83M vs. MDNAF: $59.23M
LRMR [@Biotechnology] is valued at $416.83M. MDNAF’s [@Biotechnology] market capitalization is $59.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LRMR’s FA Score shows that 1 FA rating(s) are green whileMDNAF’s FA Score has 0 green FA rating(s).

  • LRMR’s FA Score: 1 green, 4 red.
  • MDNAF’s FA Score: 0 green, 5 red.
According to our system of comparison, LRMR is a better buy in the long-term than MDNAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LRMR’s TA Score shows that 6 TA indicator(s) are bullish while MDNAF’s TA Score has 4 bullish TA indicator(s).

  • LRMR’s TA Score: 6 bullish, 4 bearish.
  • MDNAF’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, LRMR is a better buy in the short-term than MDNAF.

Price Growth

LRMR (@Biotechnology) experienced а -4.42% price change this week, while MDNAF (@Biotechnology) price change was +1.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

LRMR is expected to report earnings on Nov 18, 2025.

MDNAF is expected to report earnings on Nov 14, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LRMR($417M) has a higher market cap than MDNAF($59.2M). LRMR YTD gains are higher at: 25.840 vs. MDNAF (-37.974). MDNAF has higher annual earnings (EBITDA): -21.81M vs. LRMR (-108.21M). LRMR has more cash in the bank: 139M vs. MDNAF (20.5M). MDNAF has less debt than LRMR: MDNAF (162K) vs LRMR (4.61M). LRMR (0) and MDNAF (0) have equivalent revenues.
LRMRMDNAFLRMR / MDNAF
Capitalization417M59.2M704%
EBITDA-108.21M-21.81M496%
Gain YTD25.840-37.974-68%
P/E RatioN/AN/A-
Revenue00-
Total Cash139M20.5M678%
Total Debt4.61M162K2,848%
FUNDAMENTALS RATINGS
LRMR vs MDNAF: Fundamental Ratings
LRMR
MDNAF
OUTLOOK RATING
1..100
2850
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
38
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3863
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (29) in the null industry is in the same range as MDNAF (38). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as MDNAF (100). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

MDNAF's SMR Rating (98) in the null industry is in the same range as LRMR (100). This means that MDNAF’s stock grew similarly to LRMR’s over the last 12 months.

LRMR's Price Growth Rating (38) in the null industry is in the same range as MDNAF (63). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

LRMR's P/E Growth Rating (100) in the null industry is in the same range as MDNAF (100). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LRMRMDNAF
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
Aroon
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APHP0.200.03
+20.58%
American Picture House Corporation
ECSTX27.510.17
+0.62%
Eaton Vance Large-Cap Value C
JCNCX26.820.04
+0.15%
Janus Henderson Contrarian C
JDVAX16.940.02
+0.12%
JPMorgan Diversified A
GLATF0.50N/A
+0.08%
Global Atomic Corp.

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ARCT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+13.79%
ARCT - LRMR
46%
Loosely correlated
+3.11%
MLTX - LRMR
46%
Loosely correlated
+13.00%
TERN - LRMR
44%
Loosely correlated
+2.49%
ACLX - LRMR
44%
Loosely correlated
+3.44%
ATXS - LRMR
44%
Loosely correlated
-2.21%
More

MDNAF and

Correlation & Price change

A.I.dvisor tells us that MDNAF and LRMR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDNAF and LRMR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNAF
1D Price
Change %
MDNAF100%
-1.36%
LRMR - MDNAF
25%
Poorly correlated
+13.79%
VIR - MDNAF
25%
Poorly correlated
+1.24%
STOK - MDNAF
23%
Poorly correlated
+2.98%
CGEM - MDNAF
23%
Poorly correlated
+2.61%
PTCT - MDNAF
22%
Poorly correlated
+3.73%
More